Retatrutide

You can buy retatrutide from Peptide Lab as a laboratory-verified research peptide with 99.4% purity, for research purposes only. Retatrutide is an investigational molecule: a so-called triple agonist that acts simultaneously on the GIP, GLP-1 and glucagon receptors. It is supplied as a lyophilised powder, 30 mg per vial, and is one of the most talked-about compounds in metabolic research.

Important: research material, not a medicine

Retatrutide has not (yet) been approved as a medicinal product by the FDA, EMA or other regulatory authorities and is currently undergoing clinical development by the manufacturer. Peptide Lab supplies Retatrutide exclusively as research material — not as a slimming aid, not for human or animal consumption, and without any medical or health claims.

Who is Retatrutide intended for?

Retatrutide is intended for researchers and laboratories studying metabolic signalling pathways, receptor pharmacology and energy metabolism. Related research compounds can be found under AOD-9604 and MOTS-C, or in the Fat Loss & Metabolism category.

Why Peptide Lab?

• Verified purity of 99.4% by HPLC and mass spectrometry.
• Batch documentation available; molecular weight per CoA.
• Lyophilised powder, 30 mg per vial.
• Fast, discreet EU delivery.

Specifications at a glance

• Form: freeze-dried powder
• Packaging: 30 mg per vial
• Purity: 99.4%
• Molecular weight: See CoA
• Laboratory certificate: available on request
• For laboratory and research purposes only

Retatrutide is known as a triple agonist because it simultaneously activates three receptors involved in metabolism: the GIP receptor, the GLP-1 receptor and the glucagon receptor. Each of these pathways plays a role in the regulation of energy balance.

Mechanism of action under investigation

Research is being conducted to investigate how the simultaneous activation of these three receptors influences the signals relating to blood sugar, satiety and energy expenditure. This combined mechanism of action makes Retatrutide an interesting subject for study within receptor pharmacology, as it reveals the interaction between multiple metabolic pathways.

This description relates to the mechanism of action as studied in scientific research. It does not constitute evidence of safety or efficacy outside a controlled research setting, and no therapeutic claims are made in this regard.

As three receptor pathways are involved simultaneously, Retatrutide is a complex subject of study: researchers are attempting to determine which part of an observed effect is associated with which receptor. A pure, well-characterised starting material is essential in this regard to ensure the reliability of the results.

Retatrutide was developed by Eli Lilly and is being investigated by the manufacturer as part of an extensive clinical programme into type 2 diabetes and obesity. It is a first-in-class triple agonist and is currently in phase 3 of clinical development.

• Research focus: combined GIP, GLP-1 and glucagon receptor activation.
• Research focus: regulation of blood sugar and energy metabolism.
• Research focus: metabolic signalling pathways in preclinical and clinical models.

Status of human research

Despite the ongoing clinical programme, Retatrutide is not currently approved as a medicinal product in any major market. All results from clinical trials are the property of the manufacturer’s research programme and do not imply anything regarding the use of the research material on its own. As a research peptide, Retatrutide is intended by Peptide Lab exclusively for laboratory and research purposes. Always refer to the accompanying certificate of analysis for quality documentation.

In research practice, this means that the value of individual research materials lies in their quality and documentation, not in promises regarding outcomes. You should therefore always ensure that purity is documented, that there is a clear batch number, and that each experiment is carefully recorded.

Retatrutide is supplied as a lyophilised powder and is reconstituted in the laboratory using bacteriostatic water. The steps below describe only the laboratory procedures for research purposes.

1. 1Allow the vial and the bacteriostatic water to reach room temperature.
2. 2Wipe the rubber stoppers of both vials with an alcohol wipe.
3. 3Allow the bacteriostatic water to run slowly down the side of the vial; do not direct it straight onto the powder.
4. 4Gently swirl the vial until everything has dissolved; do not shake.
5. 5Store the solution in the fridge and label it with the date and batch number.

Supplies such as bacteriostatic water, insulin syringes and alcohol wipes can be found under ‘Lab & Accessories’. These instructions relate to laboratory use; no dosage for consumption is expressly provided.

Thorough documentation

For each experiment, record the concentration, the date of reconstitution and the batch number. As Retatrutide is a much-discussed research compound, accurate, traceable documentation is particularly important for the reliability and reproducibility of your research.

Store Retatrutide in lyophilised (powder) form in a cool, dark place. The peptide is most stable when unopened and lyophilised.

Practical storage tips

• Powder form: for long-term storage, store preferably in the freezer (-20 °C); the fridge (2–8 °C) is sufficient for short-term storage.
• After reconstitution: store the solution in a cool place (2–8 °C) and use it within a few weeks.
• Protect the vial from light, heat and repeated temperature fluctuations.
• Write the reconstitution date and the batch number on the vial.

Proper cold storage helps to maintain the purity and integrity of the research material.